Dr. Craig Thompson Leads New Study for CHF: Noted in Cardiology Journal Article

CAMBRIDGE, June 4 -- Heart Disease, the nation's number one killer, affects 8 million per year. Congestive Heart Failure (CHF) affects 5 million who currently live with the disease. Craig A. Thompson, MD, headed a collaborative team -- whose work for this project was supported by CIMIT. The team, Craig A. Thompson, MD, Boris A. Nasseri, MD, Joshua Makower, MD, Stuart Houser, MD, Michael McGarry, MSC, Theodore Lamson, PHD, Irina Pomerantseva, MD, PHD, John Y. Chang, MS, ME, Herman K. Gold, MD, FACC, Joseph P. Vacanti, MD, and Stephen N. Oesterle, MD, FACC, consists of collaborators from Harvard, MIT, and Beth Israel Deaconess Medical Center. Dr. Thompson is a Clinical and Research Fellow at MGH/Harvard Medical School in Interventional Cardiology, and is also part of the Cardiovascular Device Development Laboratory, and the Tissue Engineering and Organ Fabrication Laboratory. Published in the Journal of the American College of Cardiology, the article discussed a potentially new treatment for CHF. They determined that a catheter can provide "direct cell, gene, or medication delivery" that is safe and accurate. Industry supporters included TransVascular and Pfizer, Inc.